- |||||||||| Lampit (nifurtimox) / Bayer
The Truths About the Risk of Chagas Disease Reactivation After Heart Transplantation (Ballroom A) - Jan 19, 2025 - Abstract #ISHLT2025ISHLT_1568;
Pts with CD reactivation were treated with nifurtimox or benznidazole...When comparing the CD re-activation group to pts with no re-activation or to the control group, no statistically significant differences were recorded in 1-year survival, or 1-year freedom from ACR, AMR, CAV, NF-MACE, or LVD.Conclusion Pts undergoing HTx for CC are at risk of reactivation requiring antibiotic treatment. However, their clinical outcomes at 1-year post-HTx were similar to those with no reactivation or pts with no history of CD.
- |||||||||| Lampit (nifurtimox) / Bayer
Journal, Polymerase Chain Reaction: Usefulness of polymerase chain reaction tests in Chagas disease studies. (Pubmed Central) - Jan 16, 2025
In clinical studies, PCR has been used to assess the effectiveness of Nifurtimox and Benznidazole in treating acute and chronic Chagas patients...Based on this limiting factor, among others, we do not believe that PCR is an appropriate gold standard test for Chagas in clinical and preclinical studies. Other diagnostic methods, such as serological and biomarker tests, should be used in conjunction with PCR techniques for more accurate diagnosis of Chagas.
- |||||||||| Lampit (nifurtimox) / Bayer
Journal: Discovery of a new eugenol-benznidazole hybrid active against different evolutive stages of Trypanosoma cruzi. (Pubmed Central) - Jan 14, 2025
Chagas disease (CD) is a life-threatening illness caused by the protozoan Trypanosoma cruzi and there are only two drugs currently available for pharmacotherapy of this neglected infection (benznidazole and nifurtimox)...cruzi nitroreductase type I - TcNRT, trypanothione reductase - TR and mitochondrial membrane depolarization), but none of these metabolic pathways seem to be related to the mechanism of action of this compound. All in vitro assays employed the T. cruzi Y strain which exhibits partial resistance to benznidazole and these results indicate compound 8 as a new promising hit for the development of drug candidates to treat CD.
- |||||||||| Lampit (nifurtimox) / Bayer, cisplatin / Generic mfg.
Journal: Metal (Au, Pt, Pd, Ni) Bis(dithiolene) complexes as dual-action agents combating cancer and trypanosomatid infections. (Pubmed Central) - Jan 11, 2025
These findings highlight the need for further studies to understand how these resistance mechanisms contribute to treatment failure and constitute a biological barrier to drug action. Compared to auranofin (AF) and cisplatin (CP), two reference drugs in clinical use, all complexes showed high anticancer activities against A2780 ovarian cancer cells (IC50 values of 0.6-3.8
- |||||||||| Journal: Identifying inhibitors of Trypanosoma cruzi nucleoside diphosphate kinase 1 as potential repurposed drugs for Chagas' disease. (Pubmed Central) - Jan 8, 2025
The treatment is limited to only two drugs, benznidazole (BZL) and nifurtimox (NFX), introduced more than fifty years ago and no new advances have been made since then...Four medicines were selected and evaluated in vitro, ketorolac (KET, an anti-inflamatory), dutasteride (DUT, used to treat benign prostatic hyperplasia), nebivolol and telmisartan (NEB and TEL, used to treat high blood pressure)...Finally, transgenic epimastigotes with increased expression of TcNDPK1 were more resistant to TEL and NEB, suggesting that TcNDPK1 is at least one of the molecular targets. In view of the results, NEB and TEL could be repurposed medicines for Chagas' disease therapy.
- |||||||||| Lampit (nifurtimox) / Bayer
Preclinical, Journal: In Vitro Evaluation of New 5-Nitroindazolin-3-one Derivatives as Promising Agents against Trypanosoma cruzi. (Pubmed Central) - Oct 26, 2024
Current treatments for this disease, benznidazole and nifurtimox, have limited efficacy and may cause side effects...The lipophilicity of the studied series was shown to influence their activity, and the nitro group was found to play a crucial role in generating free radicals. Further investigations are needed of derivatives with comparable lipophilic characteristics and the location of the nitro group in different positions of the base structure.
- |||||||||| Lampit (nifurtimox) / Bayer
Journal: Semisynthetic Ecdysteroid Cinnamate Esters and tert-Butyl Oxime Ether Derivatives with Trypanocidal Activity. (Pubmed Central) - Oct 17, 2024
Nevertheless, further testing is necessary to determine the ELA assay As medications to treat Chagas disease are limited to the application of benznidazole and nifurtimox, which are not ideal treatments for the chronic stage of the disease, the search for new antichagasic drug candidates is an important need...The compound was similarly potent to benznidazole (IC50 = 3.8
- |||||||||| Lampit (nifurtimox) / Bayer
Journal: 1,3,4-oxadiazoles as inhibitors of the atypical member of the BET family bromodomain factor 3 from Trypanosoma cruzi (TcBDF3). (Pubmed Central) - Oct 16, 2024
Treatment is based on two compounds, namely, benznidazole (BZ) and nifurtimox, but chronic cases pose several challenges...Furthermore, TcBDF3 was classified for the first time as an atypical divergent member of the bromodomain extraterminal family found in protists and plants. These results make TcBDF3 a unique target due to its localization and known functions not shared with higher eukaryotes, which holds promise for Chagas disease treatment.
- |||||||||| Lampit (nifurtimox) / Bayer
Does the run-in phase add when assessing safety of trypanocidal therapies? The experience of the EQUITY trial (Convention Center - Hall I-1 (1st Floor); In-Person-Only) - Oct 11, 2024 - Abstract #ASTMH2024ASTMH_3079;
The EQUITY trial tested a 120 day treatment including Nifurtimox, Benznidazole or placebo (PBO) among T. cruzi seropositive young adults with no cardiomyopathy...Twenty days may not be enough to notice receding symptoms after stopping active treatment. At the cost of inducing some nocebo effect and excluding some candidates, the run-in improves the risk-benefit assessment of therapies for neglected tropical diseases.
- |||||||||| Lampit (nifurtimox) / Bayer
Immunomodulation Effect of Hookworm Proteins on Chronic Chagasic Liver Models (Convention Center - Hall I-1 (1st Floor); In-Person-Only) - Oct 11, 2024 - Abstract #ASTMH2024ASTMH_2266;
Unfortunately, patients with Chronic Chagas disease lack a definitive cure, relying instead on managing symptoms with drugs like Benznidazole and Nifurtimox which have serious side effects of toxicity...Control groups remained untreated or received a 14-day regimen of 25mg/kg aspirin in their drinking water...Both AIP-1 and AIP-2 significantly reduced pSTAT3 levels in the liver, indicating the reduced inflammation pathway. We will discuss further the immunomodulatory effects of AIP-1 and AIP-2 specifically on hepatic immunity in a mouse model of Chronic T. cruzi infection.
- |||||||||| Fexinidazole Winthrop (fexinidazole) / Sanofi
Consideration of Fexinidazole as a Novel Treatment Option for rhodesiense-Human African Trypanosomiasis (Convention Center - Hall I-1 (1st Floor); In-Person-Only) - Oct 11, 2024 - Abstract #ASTMH2024ASTMH_2263;
WHO continues to track cases closely as elimination efforts are ongoing. US physicians are encouraged to discuss management of patients with suspected HAT with subject matter experts at Centers for Disease Control and Prevention who can provide treatment guidance and report confirmed cases to WHO.
- |||||||||| Lampit (nifurtimox) / Bayer
Preclinical, Journal: Exploring Quinazoline Nitro-Derivatives as Potential Antichagasic Agents: Synthesis and In Vitro Evaluation. (Pubmed Central) - Sep 29, 2024
The current antichagasic drugs nifurtimox and benznidazole have inconveniences of toxicity; therefore, the search for alternative therapeutic strategies is necessary...Also, compounds 2-4 were not toxic to the human control cells, showing high selectivity index. The quinazoline nitro derivatives have potential use as antichagasic agents.
- |||||||||| Lampit (nifurtimox) / Bayer
Review, Journal: Unraveling the Missing Pieces: Exploring the Gaps in Understanding Chagas Cardiomyopathy. (Pubmed Central) - Sep 17, 2024
It also emphasizes the challenges involved in the diagnosis of the asymptomatic indeterminate phase and has focused on several diagnostic techniques, including echocardiography, electrocardiogram (ECG), magnetic resonance imaging (MRI), and nuclear imaging in diagnosing symptomatic Chagas cardiomyopathy. In this article, we have also provided a brief overview of the current treatment of Chagas cardiomyopathy, which is not etiology-specific but instead
- |||||||||| Lampit (nifurtimox) / Bayer
Journal: What are the translational challenges associated with Chagas disease drug discovery? (Pubmed Central) - Sep 13, 2024
The biological results demonstrated the potential of this new class of compounds, since three of them 19-21 showed inhibitory activity on proliferation, in the order of 50%, in the in vitro assay against epimastigotes of T. cruzi (Strain Y sensitive to nifurtimox and benznidazole) and promastigotes of L. donovani, at a single concentration of 50 ?M. No abstract available
- |||||||||| Lampit (nifurtimox) / Bayer
Review, Journal: A guide for the generation of repositories of clinical samples for research on Chagas disease. (Pubmed Central) - Aug 15, 2024
Currently, 2 anti-parasitic drugs are available to treat the disease (nifurtimox and benznidazole), but diagnostic methods require of a relatively complex infrastructure and trained personnel, limiting its widespread use in endemic areas, and the access of patients to treatment...The manual can be adapted according to the resources of each laboratory, to guarantee that samples are obtained in a reproducible way, favouring the exchange of data among different work groups, and their generalizable evaluation and analysis. The main objective of this is to accelerate the development of new diagnostic methods and the identification of biomarkers for Chagas disease.
- |||||||||| Lampit (nifurtimox) / Bayer
Journal: Nifurtimox (Lampit) for Chagas disease. (Pubmed Central) - Aug 13, 2024
The main objective of this is to accelerate the development of new diagnostic methods and the identification of biomarkers for Chagas disease. No abstract available
- |||||||||| Lampit (nifurtimox) / Bayer
Review, Journal: Chagas Disease: Epidemiology, Diagnosis, and Treatment. (Pubmed Central) - Aug 8, 2024
Use of antiparasitics during chronic chagas disease should be further explored. Additionally, future research identifying other markers of infection would be valuable to defining cure from infection.
- |||||||||| Lampit (nifurtimox) / Bayer
Preclinical, Review, Journal: Exploring the Dimensions of Pre-Clinical Research: 3D Cultures as an Investigative Model of Cardiac Fibrosis in Chagas Disease. (Pubmed Central) - Jul 27, 2024
Benznidazole (BZ) and Nifurtimox (NF) are trypanocidal drugs with few effects on the clinical manifestations of the chronic disease...These primary cardiac spheroids exhibit morphological and functional characteristics that are similar to heart tissue, making them an interesting model for studying CD cardiac fibrosis. Here, we aim to demonstrate that our primary cardiac spheroids are great preclinical models which can be used to develop new insights into CD cardiac fibrosis, presenting advances already achieved in the field, including disease modeling and drug screening.
- |||||||||| Lampit (nifurtimox) / Bayer
Biomarker, Trial completion, Trial completion date: TESEO: New Therapies and Biomarkers for Chagas Infection (clinicaltrials.gov) - Jul 17, 2024
P2, N=450, Completed,
Here, we aim to demonstrate that our primary cardiac spheroids are great preclinical models which can be used to develop new insights into CD cardiac fibrosis, presenting advances already achieved in the field, including disease modeling and drug screening. Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> May 2024
- |||||||||| Lampit (nifurtimox) / Bayer
Journal: New 2-nitroimidazole-N-acylhydrazones, analogs of benznidazole, as anti-Trypanosoma cruzi agents. (Pubmed Central) - Jul 3, 2024
Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> May 2024 Currently, only two drugs, nifurtimox and benznidazole (BNZ), are approved for its treatment...The biological results demonstrated the potential of this new class of compounds, since eight compounds were potent and selective in the in vitro assay against T. cruzi amastigotes and trypomastigotes using a drug-susceptible strain of T. cruzi (Tulahuen) (IC50?=?4.3-6.25?
- |||||||||| Lampit (nifurtimox) / Bayer
Preclinical, Journal: A Promising Amphotericin B Derivative Induces Morphological Alterations, Mitochondrial Damage, and Oxidative Stress In Vitro and Prevents Mice from Death Produced by a Virulent Strain of Trypanosoma cruzi. (Pubmed Central) - Jun 27, 2024
The medical treatment is based on two compounds, benznidazole and nifurtimox, with limited effectiveness and that produce severe side effects; consequently, there is an urgent need to develop new, safe, and effective drugs...Our results show that the A21 increased the reactive oxygen species and reduced the mitochondrial membrane potential, affecting the morphology, metabolism, and cell membrane permeability of T. cruzi in vitro. Even more important was finding that in an in vivo murine model of infection, A21 in combination with benznidazole was able to reduce blood parasitemia, diminish the immune inflammatory infiltrate in skeletal muscle and rescue all the mice from death due to a virulent T. cruzi strain.
- |||||||||| Fexinidazole Winthrop (fexinidazole) / Sanofi, Lampit (nifurtimox) / Bayer
Journal: The Evolving Spectrum of Human African Trypanosomiasis. (Pubmed Central) - Jun 25, 2024
Advances in HAT neuropathogenesis have been steady though largely incremental, with a particular focus on the role of the BBB in parasite entry into the Central Nervous System (CNS), and the relevant importance of both innate and adaptive immunity. While the WHO goal of elimination of HAT as a public health problem by 2020 has probably been achieved, it remains to be seen whether the second more ambitious goal of interruption of transmission of HAT by 2030 will be attained.
- |||||||||| Lampit (nifurtimox) / Bayer, Noxafil (posaconazole) / Merck (MSD)
Review, Journal: Tackling the Challenges of human Chagas Disease: a Comprehensive Review of Treatment Strategies in the Chronic Phase and Emerging Therapeutic Approaches. (Pubmed Central) - Jun 17, 2024
Additionally, other therapies using combinations of these drugs with other substances such as allopurinol, itraconazole, ravuconazole, ketoconazole, posaconazole and amiodarone are also reported. The importance of early diagnosis, especially in pediatric patients, is also discussed, emphasizing the need to identify the disease in its early stages to improve the chances of successful treatment.
- |||||||||| Lampit (nifurtimox) / Bayer
Biomarker, Trial completion date: TESEO: New Therapies and Biomarkers for Chagas Infection (clinicaltrials.gov) - Jun 9, 2024
P2, N=450, Active, not recruiting,
The importance of early diagnosis, especially in pediatric patients, is also discussed, emphasizing the need to identify the disease in its early stages to improve the chances of successful treatment. Trial completion date: Dec 2025 --> Jul 2025
- |||||||||| lovastatin / Generic mfg.
Preclinical, Journal: Unveiling Lovastatin's Anti-Inflammatory Potential in Mouse's Brain during Acute Trypanosoma cruzi Infection. (Pubmed Central) - May 24, 2024
CD was discovered 114 years ago, and until today, only two drugs have been available for clinical treatment: benznidazole and nifurtimox...However, LOV prevented the increase in F4/80+ cells and ICAM-1 levels in the brain caused by acute infection with T. cruzi. These results suggest an anti-inflammatory activity of LOV, but more studies are needed to elucidate the role of LOV in CD acute infection.
- |||||||||| Lampit (nifurtimox) / Bayer
Journal: A woman in her seventies with fever and convulsions. (Pubmed Central) - May 15, 2024
Nifurtimox was given as an adjunctive treatment...Microscopy of parasites in spinal fluid revealed the diagnosis. The WHO provided antiparasitic medications, and despite a severe prognosis, the patient made a full recovery.
- |||||||||| Lampit (nifurtimox) / Bayer
Journal: Conformational analysis and spectroscopic properties of antichagasic nifurtimox. (Pubmed Central) - May 13, 2024
Furthermore, a hypochromic effect was observed when the drug was dissolved in protic solvents. These findings offer crucial support for new drug delivery systems containing NFX while demonstrating the potential of spectrophotometric studies in establishing quality control assays for NFX drug products.
- |||||||||| Lampit (nifurtimox) / Bayer
Chagas Reactivation after Heart Transplantation: A Kiss That Keeps on Giving (Poster Hall, Exhibit Hall A, Level 2) - May 6, 2024 - Abstract #ATC2024ATC_2299;
As per AST guidelines, prospective clinical and laboratory monitoring is recommended in transplant recipients at risk of Chagas reactivation. Early identification and modification of immunosuppressive regimen is crucial to limit morbidity and mortality.
- |||||||||| Lampit (nifurtimox) / Bayer
Journal: N-Pyrazolyl- and N-Triazolylamines and -ureas as Antileishmanial and Antitrypanosomal Drugs. (Pubmed Central) - Apr 30, 2024
Whereas only low unspecific cytotoxicity at the primary peritoneal mouse macrophages (PMM) was detected, considerable cytotoxicity at MRC-5 human fibroblast cells was found for both pyrazoles 12b an 14a. The activity of pyrazole 12b against T. cruzi is 4-fold higher than its unspecific MRC-5 cytotoxicity.
- |||||||||| Lampit (nifurtimox) / Bayer
Journal: Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins. (Pubmed Central) - Mar 29, 2024
Causative treatment can be achieved with two drugs: benznidazole or Nifurtimox...However, due to the small number of samples and the short follow-up period, it is premature to conclude that this molecule serves as a criterion for sustained cure. Further studies are needed to validate tests based on these or other biomarkers to demonstrate parasitological cure.
|
